Experimental combo aims to wipe out stubborn leukemia cells
NCT ID NCT04501939
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether adding cirmtuzumab to venetoclax can clear remaining leukemia cells in people with chronic lymphocytic leukemia (CLL) who still have detectable disease after standard treatment. Only 5 participants are enrolled, and the main goal is to see if the combination can make the cancer undetectable. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cirmtuzumab (Zilovertamab) and Venetoclax (VENCLEXTA)
What this could lead to
If successful, this combination could help clear remaining leukemia cells in patients who still have detectable disease after standard treatment, potentially delaying the need for further therapy.
What could go wrong
This is a very small, early-phase trial with only 5 participants, so results may not apply to a broader population. Side effects from the drug combination are possible, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Koman Family Outpatient Pavilion
San Diego, California, 92037, United States